Promino Nutritional Sciences Valuation
Is 93X undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 93X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 93X's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 93X's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 93X?
Key metric: As 93X is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 93X's PS Ratio? | |
|---|---|
| PS Ratio | 19.4x |
| Sales | CA$324.21k |
| Market Cap | CA$5.14m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 25.6x |
| Enterprise Value/EBITDA | -0.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 93X's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.9x | ||
A069110 COSON | 0.4x | n/a | ₩4.4b |
SIMRIS B Simris Group | 10.7x | n/a | SEK 43.0m |
523120 Ador Multiproducts | 11.8x | n/a | ₹154.2m |
ALRPD Rapid Nutrition | 4.6x | 13.4% | €3.7m |
93X Promino Nutritional Sciences | 19.4x | n/a | €5.1m |
Price-To-Sales vs Peers: 93X is expensive based on its Price-To-Sales Ratio (19.4x) compared to the peer average (9x).
Price to Sales Ratio vs Industry
How does 93X's PS Ratio compare vs other companies in the European Personal Products Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 93X is expensive based on its Price-To-Sales Ratio (19.4x) compared to the European Personal Products industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is 93X's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 93X's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Revolution Beauty Group
UK£43.7m
Engages in the development, production, wholesale, and retail of beauty products in the United Kingdom, the United States, and internationally.
8UA
UK£0.16
7D
-3.7%
1Y
-45.5%
Reynolds Consumer Products
US$5.7b
Produces and sells products in cooking, waste and storage, and tableware product categories in the United States and internationally.
3ZT
US$25.00
7D
0%
1Y
4.2%
L'Oréal
€173.8b
Through its subsidiaries, manufactures and sells cosmetic products for women and men worldwide.
LOR
€322.25
7D
-4.7%
1Y
-23.5%